Using circulating tumor cells to evaluate the efficacy of irreversible electroporation for unresectasble pancreatic cancer

[1]  E. Hecht,et al.  Single-Institution Experience with Irreversible Electroporation for T4 Pancreatic Cancer: First 50 Patients , 2016, Annals of Surgical Oncology.

[2]  S. Chalikonda,et al.  Treatment of 200 locally advanced (stage III) pancreatic adenocarcinoma patients with irreversible electroporation: safety and efficacy. , 2015, Annals of surgery.

[3]  C. Bassi,et al.  Safety and Feasibility of Irreversible Electroporation (IRE) in Patients with Locally Advanced Pancreatic Cancer: Results of a Prospective Study , 2015, Digestive Surgery.

[4]  Huamin Liu,et al.  Circulating tumor cells in breast cancer and its association with tumor clinicopathological characteristics: a meta-analysis , 2014, Medical Oncology.

[5]  Chunxiao Wu,et al.  Cancer statistics: current diagnosis and treatment of pancreatic cancer in Shanghai, China. , 2014, Cancer letters.

[6]  Chien-Hung Lin,et al.  EGCG inhibits the growth and tumorigenicity of nasopharyngeal tumor-initiating cells through attenuation of STAT3 activation. , 2014, International journal of clinical and experimental pathology.

[7]  Klaus Pantel,et al.  [The circulating tumor cells: liquid biopsy of cancer]. , 2014, Klinicheskaia laboratornaia diagnostika.

[8]  Lihua He,et al.  Combination Treatment With Comprehensive Cryoablation and Immunotherapy in Metastatic Pancreatic Cancer , 2013, Pancreas.

[9]  Robert C. G. Martin.  Irreversible Electroporation of Locally Advanced Pancreatic Head Adenocarcinoma , 2013, Journal of Gastrointestinal Surgery.

[10]  M. Metcalfe,et al.  Pooled Survival and Response Data From Phase III Randomized Controlled Trials for Gemcitabine-based Regimes in the Treatment of Advanced Pancreatic Cancer , 2013, American journal of clinical oncology.

[11]  Yibin Kang,et al.  Tumor cell dissemination: emerging biological insights from animal models and cancer patients. , 2013, Cancer cell.

[12]  E. Felip,et al.  Adjuvant treatment of resected nonsmall cell lung cancer: state of the art and new potential developments , 2013, Current opinion in oncology.

[13]  Vic Velanovich,et al.  Irreversible Electroporation in Locally Advanced Pancreatic Cancer: Potential Improved Overall Survival , 2013, Annals of Surgical Oncology.

[14]  G. Narayanan,et al.  Percutaneous irreversible electroporation for downstaging and control of unresectable pancreatic adenocarcinoma. , 2012, Journal of vascular and interventional radiology : JVIR.

[15]  E. Lianidou,et al.  Molecular characterization of circulating tumor cells in breast cancer: challenges and promises for individualized cancer treatment , 2012, Cancer and Metastasis Reviews.

[16]  Caroline Dive,et al.  Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Caroline Dive,et al.  Tumorigenesis and Neoplastic Progression Evaluation of Circulating Tumor Cells and Serological Cell Death Biomarkers in Small Cell Lung Cancer Patients Undergoing Chemotherapy , 2010 .

[18]  Paula D. Bos,et al.  Metastasis: from dissemination to organ-specific colonization , 2009, Nature Reviews Cancer.

[19]  G. La Torre,et al.  A Systematic Review of Resectability and Survival After Concurrent Chemoradiation in Primarily Unresectable Pancreatic Cancer , 2009, Annals of Surgical Oncology.

[20]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[21]  K. Pienta,et al.  Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer , 2008, Clinical Cancer Research.

[22]  Michael Morse,et al.  Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  C. Rocha-Lima,et al.  Novel advances in pancreatic cancer treatment , 2008, Expert review of anticancer therapy.

[24]  Ruud H. Brakenhoff,et al.  Detection, clinical relevance and specific biological properties of disseminating tumour cells , 2008, Nature Reviews Cancer.

[25]  T. Kroll,et al.  Monitoring the response of circulating epithelial tumor cells to adjuvant chemotherapy in breast cancer allows detection of patients at risk of early relapse. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  H. Friess,et al.  Surgery for Recurrent Pancreatic Ductal Adenocarcinoma , 2007, Annals of surgery.

[27]  K. Pisters.  Adjuvant chemotherapy for non-small-cell lung cancer--the smoke clears. , 2005, The New England journal of medicine.

[28]  S Nahum Goldberg,et al.  Image-guided tumor ablation: standardization of terminology and reporting criteria. , 2005, Radiology.

[29]  J. Jeekel,et al.  Survival after surgical management of pancreatic adenocarcinoma: does curative and radical surgery truly exist? , 2005, Langenbeck's Archives of Surgery.

[30]  Alison Stopeck,et al.  Circulating tumor cells, disease progression, and survival in metastatic breast cancer. , 2004, The New England journal of medicine.

[31]  M. Dowsett,et al.  Circulating tumour cells in breast cancer. , 2004, The Lancet. Oncology.

[32]  Y. Kodera,et al.  Quantitative Detection of Disseminated Free Cancer Cells in Peritoneal Washes With Real-Time Reverse Transcriptase–Polymerase Chain Reaction: A Sensitive Predictor of Outcome for Patients With Gastric Carcinoma , 2002, Annals of surgery.

[33]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[34]  R. Livingston,et al.  [A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIa non-small-cell lung cancer]. , 2001, Cancer Radiothérapie.

[35]  S. Adak,et al.  A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer. Eastern Cooperative Oncology Group. , 2000, The New England journal of medicine.